Janet Neigel, MD
Ophthalmology · West Orange, NJNPI 1487698163
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,891 of the $89,914 with a category attached, or 86.6%. 10 manufacturers reported payments, led by Amgen at 51.0% of the total. Reporting peaked in 2020 at $29,872 and has fallen 98.1% since, to $582 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $288.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$46K
- Galderma Laboratories, L.p.$42K
- AbbVie$2K
- Revance Therapeutics, Inc.$401
- Bausch & Lomb, A Division Of Bausch Health US, LLC$100
- Tarsus Pharmaceuticals, Inc.$57
- plus $79 from 4 others
What the payments were for
- Consulting fees$450%
- Speaking & faculty fees$77,89187%
- Travel & lodging$5,7626%
- Food & beverage$6,1967%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 130 | $45,845 |
| Galderma Laboratories, L.p. | 70 | $41,698 |
| AbbVie(2 entities) | 77 | $1,734 |
| Revance Therapeutics, Inc. | 26 | $401 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Tarsus Pharmaceuticals, Inc. | 3 | $57 |
| Novartis | 2 | $29 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Acelrx Pharmaceuticals, Inc. | 1 | $15 |
| Argenx US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,914 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 168 | $1,766 |
| Epinastine Hcl | 31 | $1,381 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 18 | $794 |
| Cromolyn Sodium | 13 | $125 |
| ValacyclovirValacyclovir Hcl | 13 | $116 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $102 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in West Orange
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.